Prosigna Breast Cancer Assay Outperforms All Other Commercial Assays Tested in Updated Analysis of TransATAC Study Presented at ...
Prosigna Provides the Most Prognostic Information of Four Genomic Tests in Head-to-Head Comparison of Early Breast Cancer Node-Negative Patients Over a 10-Year Period SEATTLE, Dec. 12, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a …